Ani Pharmaceuticals (ANIP) Cash from Investing Activities (2016 - 2026)
Ani Pharmaceuticals' Cash from Investing Activities history spans 16 years, with the latest figure at -$1.4 million for Q4 2025.
- On a quarterly basis, Cash from Investing Activities rose 86.86% to -$1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$34.3 million, a 91.52% increase, with the full-year FY2025 number at -$34.3 million, up 91.52% from a year prior.
- Cash from Investing Activities hit -$1.4 million in Q4 2025 for Ani Pharmaceuticals, up from -$6.2 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ANIP hit a ceiling of $8.9 million in Q1 2024 and a floor of -$398.5 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$28.9 million across 5 years, with a median of -$4.7 million in 2023.
- The widest YoY moves for Cash from Investing Activities: up 479.64% in 2024, down 8652.95% in 2024.
- Tracing ANIP's Cash from Investing Activities over 5 years: stood at -$82.2 million in 2021, then surged by 96.18% to -$3.1 million in 2022, then plummeted by 52.1% to -$4.8 million in 2023, then tumbled by 123.5% to -$10.7 million in 2024, then skyrocketed by 86.86% to -$1.4 million in 2025.
- Business Quant data shows Cash from Investing Activities for ANIP at -$1.4 million in Q4 2025, -$6.2 million in Q3 2025, and -$6.9 million in Q2 2025.